Analyzing Shionogi & Co., Ltd. (OTCMKTS:SGIOY) & Saipem (OTCMKTS:SAPMF)

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) and Saipem (OTCMKTS:SAPMF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Shionogi & Co., Ltd. and Saipem’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shionogi & Co., Ltd.	$3.01 billion	4.45	$1.12 billion	$0.97	11.65
Saipem	$12.88 billion	0.36	$200.21 million	N/A	N/A

Shionogi & Co., Ltd. has higher earnings, but lower revenue than Saipem.

Profitability

This table compares Shionogi & Co., Ltd. and Saipem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shionogi & Co., Ltd.	35.53%	11.95%	10.56%
Saipem	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Shionogi & Co., Ltd. and Saipem, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shionogi & Co., Ltd.	0	0	0	0	N/A
Saipem	0	0	0	0	N/A

Insider and Institutional Ownership

1.9% of Shionogi & Co., Ltd. shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Shionogi & Co., Ltd. has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Saipem has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Summary

Shionogi & Co., Ltd. beats Saipem on 6 of the 8 factors compared between the two stocks.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

About Saipem

Saipem SpA provides energy and infrastructure solutions worldwide. The company operates through divisions Offshore Engineering & Construction (E&C), Onshore Engineering & Construction, and Offshore Drilling. It offers development of subsea fields and pipelaying; installation and lifting of offshore structures; and engineering, implementation, installation, maintenance, modification, and decommissioning activities. The company also provides biorefineries, geothermal energy, carbon capture, wind and solar energy, waste to energy, and renewables and green technologies; high-speed rail; premium, engineering, and smart maintenance services; and offshore and onshore services. In addition, the company provides procurement, project management, construction, and engineering integrated services for the energy industry and public markets. Saipem S.p.A. was founded in 1957 and is headquartered in Milan, Italy.